Kodiak Sciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
Kodiak Sciences Inc. (Nasdaq: KOD) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 11:15 a.m. PT. The event will focus on the company's innovative therapeutics for retinal diseases, utilizing its ABC Platform™. A live webcast will be available on Kodiak's website, allowing access for a limited time post-event.
Kodiak aims to develop transformative medicines, with its lead candidate, KSI-301, targeting age-related macular degeneration and other retinal vascular diseases.
- None.
- None.
PALO ALTO, Calif., Jan. 3, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 11:15 a.m. Pacific Time (2:15 p.m. Eastern Time).
A live webcast of the presentation will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the event.
About Kodiak Sciences Inc.
Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, Kodiak is focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Kodiak's ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, Kodiak's bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and Kodiak is expanding its early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA. For more information, please visit www.kodiak.com.
Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.
View original content:https://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-the-40th-annual-jp-morgan-healthcare-conference-301452923.html
SOURCE Kodiak Sciences Inc.
FAQ
When is Kodiak Sciences presenting at the J.P. Morgan Healthcare Conference?
Where can I watch the Kodiak Sciences presentation?
What is Kodiak Sciences' main focus?
What is Kodiak Sciences' lead product candidate?
What diseases does KSI-301 target?
